There is good reason for a Nasdaq Listing. Australian Funds don’t have Biotech Analysts so they don’t invest in Biotech, NASDAQ has a large number of highly qualified Biotech Analysts and the funds and investors follow their advice
That was again clearly explained by a Fund Manager last week. The fund manager explained exactly why Biotechs struggle on the ASX.
The funds that were largely responsible for pushing NEU’s rise were offshore.
If you want to get anything fairly valued you need to be in a market that understands whatever it is you are selling.
There is good reason for a Nasdaq Listing. Australian Funds...
-
- There are more pages in this discussion • 1,285 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.5¢ |
Change
-0.004(6.78%) |
Mkt cap ! $409.9M | |||
| Open | High | Low | Value | Volume |
| 6.0¢ | 6.1¢ | 5.5¢ | $2.467M | 43.41M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 55893 | 5.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.6¢ | 584888 | 14 |
View Market Depth
| Last trade - 15.23pm 24/06/2024 (20 minute delay) ? |
| IMU (ASX) Chart |